Report : Middle East & Africa Immunodiagnostics Market Forecast to 2030 - Regional Analysis - by Product (Enzyme-Linked Immunosorbent Assays (ELISA), Chemiluminescence Immunoassays (CLIA), Radioimmunoassays (RIA), and Others), Clinical Indication (Infectious Diseases, Hepatitis+HIV, Endocrinology, Gastrointestinal, Metabolics, and Others), and End User (Hospitals, Clinics, Diagnostic Laboratories, Academic & Research Institutes, and Others)
At 8.0% CAGR, the Middle East & Africa Immunodiagnostics Market is Speculated to be worth US$ 1,089.81 million by 2030, says Business Market Insights
According to Business Market Insights research, the Middle East & Africa immunodiagnostics market was valued at US$ 636.46 million in 2023 and is expected to reach US$ 1,089.81 million by 2030, registering a CAGR of 8.0% from 2023 to 2030. Technological advancements in immunodiagnostics and rising focus on R&D investment and expansion by key players are the critical factors attributed to the Middle East & Africa immunodiagnostics market expansion.
The current trend in immunodiagnostics is microfluidics and magnetic beads with potential commercialization. These sensitive, specific, and time-saving methodologies are essential in understanding and diagnosing health conditions, such as infectious diseases, metabolic disorders, and cardiac problems.
The increasing applications of immunodiagnostics solutions encouraged the development of targeted treatments and therapies for precision health. The prominent market players also promote assay technologies, microfluidics, and magnetic beads. For immunoassays, magnetic particles, such as Sera-Mag beads, offer a convenient alternative to plate-based ELISAs, as both rely on the same assay principle. Merck KGaA launched the Magna Chip Protein A magnetic beads. This recombinant Protein A is covalently bound to magnetic beads for chromatin immunoprecipitations (Chip assays), providing users with a faster, reproducible, and more efficient reagent for collecting immunocomplexes than agarose beads.
In microfluidics, some immunodiagnostics target single biomarkers. However, a recent trend shows the detection of multiple analytes according to the complexity and the need to make early reliable diagnoses.
In September 2023, Siemens Healthineers released its new CE-marked SARS-CoV-2/FluA/FluB/HRSV assay, a PCR test, and the CLINITEST Rapid COVID-19 + Influenza Antigen Test. The new FTD SARS-CoV-2/FluA/FluB/HRSV assay enables comprehensive and semi-automated molecular testing for seasonal respiratory pathogens. The combination PCR test detects and differentiates clinically relevant viruses such as SARS-CoV-2, Influenza A, Influenza B, and HRSV A/B.
On the contrary, inadequate reimbursement scenario hurdles the growth of Middle East & Africa immunodiagnostics market.
Based on product, the Middle East & Africa immunodiagnostics market is segmented into enzyme-linked immunosorbent assays (ELISA), chemiluminescence immunoassays (CLIA), radioimmunoassays (RIA), and others. The enzyme-linked immunosorbent assays (ELISA) segment held 55.1% share of Middle East & Africa immunodiagnostics market in 2023, amassing US$ 350.43 million. It is projected to garner US$ 594.51 million by 2030 to expand at 7.8% CAGR during 2023–2030. The chemiluminescence immunoassays (CLIA) segment is further segmented into vitamin D assay market, HIV detection market, HIV ag/ab combo assay market, and other tests.
Based on clinical indication, the Middle East & Africa immunodiagnostics market is segmented into infectious diseases, hepatitis+HIV, endocrinology, gastrointestinal, metabolics, and others. The infectious diseases segment held 45.2% share of Middle East & Africa immunodiagnostics market in 2023, amassing US$ 287.97 million. It is projected to garner US$ 511.44 million by 2030 to expand at 8.6% CAGR during 2023–2030. The infectious diseases segment is further segmented into COVID-19, tuberculosis, lyme, infection management, zika, treponema, torch, measles and mumps, VZV, and EBV. The endocrinology segment is further segmented into hypertension, growth, diabetes, thyroid, and reproductive endocrinology.
Based on end user, the Middle East & Africa immunodiagnostics market is segmented into hospitals, clinics, diagnostic laboratories, academic & research institutes, and others. The hospitals segment held 43.2% share of Middle East & Africa immunodiagnostics market in 2023, amassing US$ 275.03 million. It is projected to garner US$ 460.80 million by 2030 to expand at 7.7% CAGR during 2023–2030.
Based on country, the Middle East & Africa immunodiagnostics market is segmented into Saudi Arabia, South Africa, the UAE, and the Rest of Middle East & Africa. Our regional analysis states that Saudi Arabia captured 33.9% share of Middle East & Africa immunodiagnostics market in 2023. It was assessed at US$ 215.44 million in 2023 and is likely to hit US$ 361.27 million by 2030, exhibiting a CAGR of 7.7% during 2023–2030.
Key players operating in the Middle East & Africa immunodiagnostics market are Abbott Laboratories; bioMerieux SA; Danaher Corp; DiaSorin SpA; F. Hoffmann-La Roche Ltd; PerkinElmer Inc; Shenzhen Mindray Bio-Medical Electronics Co., Ltd.; Siemens Healthcare GmbH; Svar Life Science AB; and Thermo Fisher Scientific Inc, among others.
Contact Us
Contact Person: Sameer Joshi
Phone: +1-646-491-9876
Email Id: sales@businessmarketinsights.com